Clinical variables
|
Age
|
58.7 (8.3)
|
48.3 (7.7)
|
0.03
|
Sex, n (% women)
|
5 (83 %)
|
9 (100 %)
|
0.40
|
Ethnicity, n (% Caucasian)
|
5 (83 %)
|
5 (56 %)
|
0.58
|
BMI
|
22.4 (2.6)
|
24.5 (5.00)
|
0.30
|
Smoking, n (% past)
|
4 (67 %)
|
2 (22 %)
|
0.14
|
SSc subtype, n (% diffuse)
|
3 (50 %)
|
6 (67 %)
|
0.62
|
mRSS
|
12.7 (12.6)
|
16.6 (14.2)
|
0.59
|
GER symptoms, n (% present)
|
5 (83 %)
|
5 (56 %)
|
0.58
|
Dysphagia, n (% present)
|
3 (50 %)
|
3 (33 %)
|
0.62
|
Patulous esophagus HRCT, n (% present)
|
5 (83 %)
|
7 (78 %)
|
1.00
|
SSc disease duration (mo.)
|
153.7 (132.5)
|
83.7 (89.5)
|
0.29
|
GI symptom duration (mo.)
|
61.8 (62.2)
|
84.4 (87.0)
|
0.57
|
SSc autoantibodies, n (% positive)
|
N = 5
| | |
• Scl-70
|
3 (50 %)
|
3 (33 %)
|
0.26
|
• ACA
|
1 (17 %)
|
0
| |
• RNA pol III
|
1 (17 %)
|
4 (44 %)
| |
• Negative
|
0
|
2 (22 %)
| |
• Missing
|
1 (17 %)
|
0
| |
Primary ANA pattern, n (% present)
| | | |
• Centromere
|
1 (17 %)
|
0
|
0.08
|
• Nucleolar
|
1 (17 %)
|
0
| |
• Speckled
|
1 (17 %)
|
7 (78 %)
| |
• Homogenous
|
3 (50 %)
|
2 (22 %)
| |
+ Mycophenolate, n (% current)
|
1 (17 %)
|
5 (56 %)
|
0.29
|
+Proton pump inhibition, N (% current)
|
6 (100 %)
|
9 (100 %)
|
N/A
|
FVC % predicted
|
70.2 (23.9)
|
88.9 (14.8)
|
0.13
|
TLC % predicted
|
81.8 (20.2)
|
100.6 (18.0)
|
0.13
|
DLCO % predicted
|
46.5 (17.5)
|
67.1 (20.3)
|
0.06
|
ILD present on HRCT, n (%)
|
5 (83 %)
|
7 (78 %)
|
1.00
|
Endoscopy, n (% present)
|
Esophagitis
|
4 (67 %)
|
5 (56 %)
|
1.00
|
Hiatal hernia
|
5 (83 %)
|
7 (78 %)
|
1.00
|
Pathology
|
Squamous epithelial lymphocytes
|
10.0 (8.7)
|
5.6 (5.9)
|
0.36
|
Basal cell hyperplasia, n (%)
|
N = 5
|
N = 7
| |
• 0
|
1 (17 %)
|
3 (33 %)
|
0.75
|
• 1
|
3 (50 %)
|
5 (56 %)
| |
• 2
|
1 (17 %)
|
0
| |
Degree of collagen deposition in lower esophageal biopsies, n (%)
|
N = 4
|
N = 4
| |
• 0
|
2 (33 %)
|
4 (44 %)
|
0.38
|
• 1
|
1 (17 %)
|
0
| |
• 2
|
1 (17 %)
|
0
| |
Candida esophagitis, n (%)
|
2 (33 %)
|
0
|
0.14
|